Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLI1 | P08151 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.36 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.35 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.32 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.32 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13709164 | 1.00 | GLI1 (0.43) | GLI1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL24687705 | 0.82 | LMNA (0.38) | LMNASMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL8343901 | 0.82 | LMNA (0.38) | LMNASMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL1978357 | 0.79 | LMNA (0.39) | LMNASMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL13709169 | 0.78 | GLI1 (0.42) | GLI1 | |
| SCHEMBL25301025 | 0.78 | POLB (0.34) | LMNASMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL25301024 | 0.78 | POLB (0.34) | LMNASMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL2132866 | 0.77 | — | — | |
| SCHEMBL8920712 | 0.77 | — | — | |
| SCHEMBL3134625 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927460-B2 | Biocide compositions comprising derivatives of pyroglutamic acid | COGNIS IP MANAGEMENT GMBH (DE) | 2015-01-06 | — | — | US | claimed |
| US-20130102467-A1 | Biocide Compositions Comprising Derivatives of Pyroglutamic Acid | COGNIS IP MANAGEMENT GMBH (DE) | 2013-04-25 | — | — | US | claimed |
| WO-2011072811-A2 | BIOCIDE COMPOSITIONS COMPRISING DERIVATIVES OF PYROGLUTAMIC ACID | COGNIS IP MANAGEMENT GMBH (DE) | 2011-06-23 | — | — | WO | claimed |
| EP-2335480-A1 | Biocide compositions comprising derivatives of pyroglutamic acid | Cognis IP Management GmbH (DE) | 2011-06-22 | — | — | EP | claimed |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20150094206-A1 | Biocide Compositions Comprising Derivatives Of Pyroglutamic Acid | COGNIS IP MAN GMBH (DE) | 2015-04-02 | — | — | US | disclosed |
| US-8927460-B2 | Biocide compositions comprising derivatives of pyroglutamic acid | COGNIS IP MANAGEMENT GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-20130102467-A1 | Biocide Compositions Comprising Derivatives of Pyroglutamic Acid | COGNIS IP MANAGEMENT GMBH (DE) | 2013-04-25 | — | — | US | disclosed |
| WO-2011072811-A2 | BIOCIDE COMPOSITIONS COMPRISING DERIVATIVES OF PYROGLUTAMIC ACID | COGNIS IP MANAGEMENT GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
| EP-2335480-A1 | Biocide compositions comprising derivatives of pyroglutamic acid | Cognis IP Management GmbH (DE) | 2011-06-22 | — | — | EP | disclosed |
| EP-1513814-B1 | NOVEL PIPERIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-03-17 | — | — | EP | disclosed |
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | SDHA, SDHB, NQO1 | GLI1 1098/4885LMNA 1291/4885SMN1; SMN2 2461/4885 |
| US-20130102467-A1 | Biocide Compositions Comprising Derivatives of Pyroglutamic Acid | GLUL, GLO1, PGD | GLI1 3323/4885LMNA 2726/4885SMN1; SMN2 4455/4885 |
| US-20150094206-A1 | Biocide Compositions Comprising Derivatives Of Pyroglutamic Acid | GLUL, GLO1, PGD | GLI1 3323/4885LMNA 2726/4885SMN1; SMN2 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.